-+ 0.00%
-+ 0.00%
-+ 0.00%

Evaxion (EVAX) Q3 2026 Earnings Call Transcript

The Motley Fool·11/19/2026 19:14:40
Listen to the news
Logo of jester cap with thought bubble.

Image source: The Motley Fool.

DATE

Thursday, Nov. 19, 2026

CALL PARTICIPANTS

  • Chief Executive Officer - Helen Tayton-Martin
  • Chief Scientific Officer and Chief Operating Officer - Birgitte Rønø
  • Chief Financial Officer - Thomas Schmidt
  • Head of Investor Relations and Communications - Mads Kronborg

Need a quote from a Motley Fool analyst? Email pr@fool.com

TAKEAWAYS

  • Net Loss -- $3.5 million, compared to a profit of $4.6 million in the prior-year period due to the absence of revenue from out-licensing the EVX-B3 program.
  • Cash and Cash Equivalents -- $13.3 million as of Sept. 30, 2026, which includes proceeds of $2.2 million from the ATM program utilized in August.
  • Cash Runway -- extended to the end of 2027, driven by disciplined resource allocation and equity sales.
  • Yearly Cash Burn -- approximately $14 million, according to management expectations for the full year.
  • EVX-01 Vaccine Target Precision -- 89%, based on phase II clinical data in patients with metastatic melanoma.
  • EVX-01 Objective Response Rate -- 75%, with a complete response rate of 25% reported in the phase II advanced melanoma study.
  • EVX-01 Clinical Response Improvement -- 54%, reflecting 7 out of 13 patients who improved their response after receiving the vaccine in combination with anti-PD-1 therapy.
  • Neoantigen Response -- 86%, representing de novo immune responses rather than preexisting responses.
  • ATM Program Proceeds (October) -- $800,000, received after the close of the third quarter and contributing to the extended cash runway.
  • Research and Development Expenses -- $2.3 million, representing a decrease from $3.1 million in the third quarter of 2025 due to reduced headcount.
  • General and Administrative Expenses -- $1.4 million, which remained level with the prior-year period as lower capital market costs were offset by higher business development expenses.
  • Total Equity -- $8.1 million as of Sept. 30, 2026.
  • Debt Cancellation -- $4.1 million, recorded in 2025 in exchange for warrants issued to the European Investment Bank.
  • Potential Warrant Proceeds -- up to $1.5 million, which may be received if the European Investment Bank exercises its warrants.
  • EVX-01 T-cell Detection -- CD8+ responses were detected in 9 out of 15 evaluated patients.
  • Turnaround Time -- approximately seven weeks, representing the duration from biopsy to the administration of the personalized vaccine.
  • Neoantigen Prediction Speed -- 24 hours, utilizing the AI-Immunology platform to process patient sequencing data.
  • EVX-04 Development Timeline -- filing of the clinical trial application is expected by the end of 2026.
  • Employee Count -- 46, focused across the discovery and clinical development value chain.
  • Off-the-shelf Antigen Source -- 5 million endogenous retrovirus antigen fragments, which were evaluated by the AI platform to select the optimal sets for the EVX-04 candidate.
  • Basic and Diluted Loss Per Share -- $0.01, compared to a profit of $0.01 per share in the same quarter of the previous year.

SUMMARY

Evaxion (NASDAQ:EVAX) management announced a strategic refocus to prioritize the AI-Immunology platform toward oncology programs, specifically advancing its off-the-shelf and personalized cancer vaccines. The company reported the extension of its cash runway into the end of 2027, supported by disciplined resource allocation and at-the-market equity sales. Clinical validation for the platform was highlighted through three-year phase II data for the EVX-01 vaccine, showing high target precision and durable immune responses in metastatic melanoma. Management indicated that future development of infectious disease and autoimmune assets will be conducted exclusively through external partnerships to maximize the value of internal resources.

  • Chief Executive Officer Tayton-Martin stated, "Evaxion is now refocusing all of its own resources in the application of our AI-Immunology platform towards our oncology portfolio."
  • Management reported that the International Prix Galien Award for AI-Immunology provides external validation that the platform delivers meaningful therapeutic product candidates.
  • Rønø indicated that the AI platform demonstrated a positive correlation between prediction scores for single neoantigens and the magnitude of observed immune responses in patients.
  • The company expects to file a clinical trial application for EVX-04, an off-the-shelf vaccine for acute myeloid leukemia, by the end of 2026.
  • Tayton-Martin reported that business development remains a high priority, with multiple parallel conversations ongoing to leverage recent clinical data.

INDUSTRY GLOSSARY

  • AI-Immunology: Evaxion’s proprietary artificial intelligence platform used to identify and design vaccine targets.
  • Neoantigens: Protein fragments that arise from cancer-specific mutations and are found exclusively in tumor cells.
  • Endogenous Retroviruses (ERVs): Viral sequences integrated into the human genome that can be used as targets for off-the-shelf cancer vaccines.
  • Dark Genome: The portion of the human genome that does not encode proteins and was historically considered nonfunctional.
  • ATM Program: An at-the-market equity program that allows a company to sell shares directly into the market over time.
  • CTA: A clinical trial application required to begin testing a drug candidate in humans.
  • AML: Acute myeloid leukemia, a fast-growing cancer of the blood and bone marrow.
  • GBM: Glioblastoma multiforme, an aggressive type of cancer that can occur in the brain or spinal cord.

Full Conference Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Evaxion Strategy and Business Update and Third Quarter 2026 Financial Results Webcast and Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star, one, and one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star, one, and one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Helen Tayton-Martin, Chief Executive Officer. Please go ahead.

Helen Tayton-Martin: Thank you, and good morning and welcome, to everyone to Evaxion's Strategy and Business Update for Q3. I'm Helen Tayton-Martin. I'm the Chief Executive Officer of Evaxion, and I'm joined today on the call by Birgitte Rønø, our Chief Scientific Officer and Chief Operating Officer, and Thomas Schmidt, Chief Financial Officer, Mads Kronborg, our Head of Investor Relations and Communications. In our agenda today, I will walk you through how we are refocusing our strategy to create the maximal value, and will then hand over to Birgitte, who will take us through the highlights of our R&D activities during the quarter, and some of the key data and developments with our AI-Immunology platform, which is driving this strategy shift.

Thomas will take you through the financial results for the quarter before we wrap up with some concluding remarks and take questions. As a reminder, we may make forward-looking statements during today's call, and in that context, I would refer you to our most recent filed statements. Turning to the first agenda point, our strategy update. Put very simply, Evaxion is now refocusing all of its own resources in the application of our AI-Immunology platform towards our oncology portfolio.

With Moderna's recent phase III groundbreaking data validating personalized cancer vaccines as truly capable of delivering meaningful clinical benefit in adjuvant melanoma, we have been proud and excited to share our own phase II three-year clinical data in recent weeks, in which patients with metastatic melanoma, where we used our AI-Immunology platform to predict high-quality and relevant antigens for patients, which was correlated with high precision in terms of the immune response generated, and more importantly, in deep and durable outcomes, as Birgitte will highlight later.

In addition, we have been able to use AI-Immunology to drill deeper into the dark genome and identify other types of antigens, especially endogenous retroviral elements, or ERVs, where we can identify unique and highly conserved sets of antigens to enable an off-the-shelf vaccine approach, in addition to the personalized neoantigen vaccines. We believe there is enormous opportunity in Evaxion's AI-Immunology platform to identify and develop both personalized and off-the-shelf cancer vaccines across multiple indications, customized according to antigen source and scope, and this is where maximum value lies in Evaxion. As a result, going forward, we will be focusing our own resources in the three key areas shown at the bottom of this slide.

Firstly, taking our two off-the-shelf cancer vaccines, EVX-04 in AML and EVX-05 in GBM, into the clinic, the latter in collaboration with Duke University. Secondly, we will be looking at broadening the potential of EVX-01 beyond advanced melanoma, and most likely, we expect to do this through partnership. Thirdly, we plan to continue to identify other new antigens and indications from deeper analysis of the dark genome with AI-Immunology. In terms of our pipeline going forward, we will be progressing only our oncology assets, as just mentioned.

Elsewhere, we believe we have built significant value in the preclinical assets and capabilities we have developed in the infectious disease area over many years, with EVX-B1 in Staph aureus, EVX-B2 in gonorrhea, EVX-B4 in Group A Streptococcus, and EVX-V1 in CMV. We will continue to look for partnerships for these assets and work with partners only in other infectious disease programs where the partner comes forward. In autoimmune disease, we are testing the concepts we identified for tolerogenic vaccines and autoantibody binders using AI-Immunology, and we will complete that work to validate the approach for potential partnering.

Looking to the achievements we have made in the last quarter, on business development, we have had a very busy time and continue to progress multiple parallel conversations, all leveraging the recent data and validation of AI-Immunology with the EVX-01 and the future off-the-shelf potential with EVX-04 and EVX-05, and more broadly with other indications, other cancer indications. On R&D, much of the latest three-year data for EVX-01 was presented at ESMO and SITC, as Birgitte will cover, and we will be providing a further update for the EVX-04 program at ASH next month. We completed the initial work with our EVX-B4 Group A Strep program and started the initial concept testing for the targets identified for autoimmune disease.

On the platform itself, we were truly honored to see AI-Immunology recognized on the international stage at the International Prix Galien Awards, winning the Best Digital Health Solution prize, we believe adding further validation to how the Evaxion AI platform delivers meaningful clinical benefit. Finally, we have continued to maintain rigorous discipline in managing our financial resources aligned to the greatest areas of value, as well as being able to make prudent use of our ATM to enable us to extend the runway towards the end of 2027. When we look at our milestones for 2026, we have now achieved all of them except for the filing of our EVX-04 clinical trial application.

This is on track to be filed by the end of the year, in keeping with our refocused strategy on our IO programs and capabilities. With that, I will hand over to Birgitte to take us through the key R&D and AI-Immunology updates.

Birgitte Rønø: Thank you for that, Helen. As Helen outlined, we are focusing our strategy on oncology, building on the clinical and translational evidence from our personalized EVX-01 cancer vaccine, and the broader capability of our proprietary AI platform, AI-Immunology, to discover clinically relevant cancer antigens and to design vaccines. Our priorities are, as mentioned, to advance our off-the-shelf cancer vaccines, EVX-04 and EVX-05, toward clinical development, and further to expand EVX-01's potential across indications through partnerships, and to continue mining the dark genome for cancer vaccine antigens. The scientific update that follows show the evidence behind this focus and how we are translating our AI platform's capability into oncology product opportunities. Let me start with the rationale behind personalized cancer vaccines.

Personalized cancer vaccines targets neoantigens. These are sequences that are arising from cancer-specific mutations, and they're found exclusively in the tumor, but absent in normal tissue, making them highly attractive therapeutic targets. The challenge lies in identifying which of the patient's neoantigens that will generate a tumor-targeting immune response. AI-Immunology selects the most promising neoantigens by modeling the steps from cancer-specific mutations through expression, translation, presentation on the MHC molecules, and T-cell recognition. The AI-Immunology platform sits within a broader patient-to-vaccine process. For each patient, tumor and blood samples are collected, and they undergo DNA and RNA sequencing. AI-Immunology then, based on this information, predicts the patient-specific neoantigens in 24 hours, informing the design of the personalized EVX-01 vaccine.

Following manufacture, the vaccine is then administered in combination with checkpoint inhibitors. The total turnaround time from biopsy to vaccine administration is approximately seven weeks. In our EVX-01 phase II study, we reported an 89% precision in predicting immunogenic neoantigens. I'll now turn to the clinical results and the immune response data behind this record-high precision. In our EVX-01 phase II study in advanced melanoma, the two-year results showed an objective response rate of 75% and a complete response of 25%. We also saw improvement in the response from a week 12 assessment following initiation of EVX-01 immunization.

Seven out of 13 patients who had stable disease or a partial response after 12 weeks of anti-PD-1 therapy improved their response, corresponding to 54% following EVX-01 administration. Also of importance is that EVX-01-related adverse events were limited to grade 1 and grade 2. The one-year extension provided longer follow-up in a smaller group of patients, and the clinical responses in all six patients who participated in this extension with EVX-01 monotherapy lasted until the end of the trial. Overall, these are very encouraging clinical results that demonstrated clinical benefit of EVX-01 in combination with anti-PD-1 therapy in advanced melanoma. Turning to immunogenicity, EVX-01 induces potent vaccine-specific T-cell responses against the vaccine neoantigens.

The key point is that the platform can identify antigens recognized by the immune system. EVX-01-induced vaccine-specific T-cell responses that are sustained throughout the three-year period, including in the absence of anti-PD-1 therapy, which is provided only or was provided only during the first two years. As mentioned, we were able to demonstrate a record-high vaccine target precision of 89%. That is a clear testament to the predictive power of our AI-Immunology platform. Additionally, 86% of the assessed neoantigen responses were de novo, in other words, newly induced responses rather than preexisting responses. This is important as therapy-induced new T-cells have been correlated to clinical benefit.

Let's look more closely at the phenotype of the T-cell responses and how the strength of the EVX-01-induced T-cell responses relates to AI predictions. First, EVX-01 induces both CD4+ and CD8+ antigen-specific T-cell responses. In all evaluated patients, we were able to demonstrate a CD4+ response, and in nine out of the 15 patients, we were also able to detect CD8+ responses. We are still evaluating samples from the study, so stay tuned. More immune data and biomarker data will be shared in the next year. Secondly, we were able to demonstrate a positive correlation between the AI prediction score assigned to these single neoantigens, and the magnitude of the observed immune response.

Higher prediction score also were associated with a stronger immune response. This is an important link between the platform's predictions and the biological responses measured in the patients. With that clinical and translational foundation, let's look at how AI-Immunology can be applied more broadly. The broader opportunity is to use AI-Immunology across antigen sources, cancer indications, and vaccine approaches. The platform processes complex patient data, including genomic, transcriptomic, and proteomic data, to identify and prioritize cancer antigens. As shown here, our work spans neoantigens and endogenous retrovirus, or ERVs, from the dark genome, and we are now looking at additional dark genome antigens.

That creates two complementary vaccine approaches: personalized vaccines that are tailored to an individual patient and targets private antigen, as exemplified by EVX-01 in melanoma, and off-the-shelf vaccines that are tailored to a patient population and target conserved ERV antigens, as in EVX-04 for acute myeloid leukemia and EVX-05 for GBM. The other indications shown on this slide, including head and neck, lung, ovarian, bladder, colon, esophageal, testicular, and stomach cancers, illustrate the potential breadth of the application based on deep data mining and antigen profiling of patients. The strategic point is that the platform is not confined to one cancer type or to one vaccine approach. It gives us basis for pursuing opportunities across personalized and off-the-shelf cancer vaccines.

Let's now look at AI-Immunology's key differentiators. Broad discovery across multiple antigens, sources, and high target precision. That translate into strategic product opportunities for both personalized and off-the-shelf cancer vaccines across more patients and cancer types. AI-Immunology, as mentioned, explores neoantigens from cancer-specific somatic mutations, ERV antigens from genome-integrated viral sequences, and additional dark genome antigens which are currently in development. This provides a broader antigen repertoire. With our record-high target precision demonstrated in clinical trials, exemplified by the 89% vaccine target precision rate in EVX-01 phase II trial, we are well-positioned in finding the right targets.

The core component of AI-Immunology is instrumental in identifying the most relevant T-cell epitopes, and this one is a key driver of the high target precision rate. The core code is antigen type agnostic and provides a common foundation for designing high-precision cancer vaccines irrespective of the antigen of choice. These two AI-Immunology differentiators, broad antigen repertoire and high target precision, translate into strategic product opportunities. Greater antigen breadth significantly increases the chance of finding effective targets for more patients and cancer types. The precision at the target level increases the likelihood of clinical success, as it is the foundation for stronger clinical outcome.

Taking together, this positions AI-Immunology not just as a platform for a single vaccine, but as a foundation for developing a broader portfolio of cancer vaccines, combining the opportunity to reach more patients with the potential for stronger clinical outcome. EVX-04 is a concrete example of how we are translating this broader discovery capability into an off-the-shelf cancer vaccine program. Starting with sequencing data from AML patients, we identified ERV tumor antigens. From 5 million ERV antigen fragments and corresponding MHC ligands, AI-Immunology selected the 16 optimal antigen fragment sets. Currently, multiple vaccine candidates were designed and tested, and the lead candidate is now moving forward in GMP manufacturing.

We are now progressing through final preclinical testing and validation of the selected ERV antigens alongside activities to enable clinical trial application, or CTA, with the submission expected in the second half of this year. In summary, AI-Immunology combines broad antigen discovery with high target precision. We can identify cancer antigens from multiple sources, neoantigens, ERVs, and additional dark genome antigen approaches in development using the same core predictive technology across antigen sources. Together, these capabilities create the opportunity to identify relevant targets for more patients and more cancer types, supporting both personalized and off-the-shelf approaches, and providing a foundation for a stronger clinical outcome. With that, I'll hand over to Thomas to present our Q3 financial results.

Thomas Schmidt: Yes, thank you, Birgitte, and also a warm welcome from my side to everyone on the call. Let me take you through the financial results for Q3, and we shift to the financial highlights. As key financial highlights for the quarter, we have now successfully further extended our cash runway now towards the end of 2027. This is from earlier communications that we've done where we spoke about cash runway into the second half of 2027. This we've managed to do through, first and foremost, utilizing our ATM program, however, also through our continued disciplined resource allocation.

Both the ATM and certainly also our continued disciplined resource allocation is also in support of our now refocused strategy and the updated pipeline, as we have just heard and seen. We are on track for the full year to deliver according to our financial plan. We also still expect an unchanged yearly cash burn rate of approximately $14 million, as also earlier communicated. Cash position obviously have improved throughout the year, and now also reflects that in the extended runway. Looking into our profit and loss details, the statement clearly shows a net loss for the quarter of $3.5 million, which compares to $4.6 million profit in the same quarter last year.

Main reason for that lies within the recognized revenue. We've not recorded any recognized revenue in Q3 this year, whereas last year, we out-licensed our EVX-B3 program to Merck, or as called in Europe, MSD. At the same time, however, this year, we have reduced our operating cost compared to last year, both within R&D due to fewer headcounts, but certainly also in G&A with lower capital market costs, while we at the same time have put more resources into BD, business development activities, and therefore costs.

Our financial income and expenses for the quarter also now reflect a more normalized financial operation of ours, where the financial expense and income relate to interest from our debt and interest from income from our bank and cash position. This compares to last year, where we had high financial income from our debt-to-equity agreement that we did with the European Investment Bank, and on the other side, we had financial expenses which related to remeasurement of our derivative liability. This derivative liability has been reduced significantly and has no longer any significant impact on our financial expenses and income.

Moving to our balance sheet, our main balance sheet items include obviously our cash position, now end of September, of $13.3 million. This includes proceeds from our ATM program of $2.2 million, which we utilized and received in August 2026. We have received further proceeds from our ATM program in October of another $800,000, but that is not reflected in the cash position end of September, however, is included in our cash runway that, as mentioned earlier, has now been extended towards the end of 2027. Equity stands at $8.1 million, which obviously also has been increased by the ATM sales in August, and obviously impacted by the net loss from the period also.

Last, but also not least, even though it is in November, important just to note also that we have filed an amendment to the Form F-1, which relates back to 2025, that settled agreement with the European Investment Bank, which now, this new amendment allows them to exercise their warrants. It's important to note that we are not selling any securities under this registration, and we will not receive any proceeds from the sales of ordinary shares. However, of course, we have received back in 2025, and recorded a debt cancellation of $4.1 million in exchange of warrants.

These warrants, once exercised, will mean that we may receive up to another $1.5 million when and if exercised by the European Investment Bank. With that, I conclude the financial for the quarter and hand it back to Helen for some concluding remarks.

Helen Tayton-Martin: Thanks, Thomas. In concluding, I think today we have set out a refocused strategy to maximize the value of our assets and capabilities in immuno-oncology, and we have set out why we are planning to do that and how we are planning to do that. In particular, we have seen continued validation of the unique capabilities that Evaxion has in AI-Immunology, as well as commented on how that impacts and drives forward individual programs.

Business development remains a key priority for the organization, with multiple parallel conversations ongoing, and we have been able to extend the runway towards the end of 2027, all of which is putting Evaxion into a strong position as we complete our milestones at the end of 2026. With that, I think we will finish the call. Thank you for listening, and be ready to take questions.

Operator: Thank you. To ask a question, you will need to press star, one, and one on your telephone and wait for your name to be announced. To withdraw your question, please press star, one, and one again. One moment for our first question. This one comes from Thomas Flaten from Lake Street Capital Markets. Please go ahead.

Thomas Flaten: Thanks for taking the questions. Helen, just to follow up on the beginning of your prepared comments. You denoted the enthusiasm in the market following the Merck and Moderna data at ESMO. Just looking back at the pivot that you are undertaking, was there a lack of interest on the infectious disease side, or has there just been overwhelming interest on the immuno-oncology side, which is part of the reason for the pivot? Or was it simply a lack of resources that puts you in the position of focusing on one versus both?

Helen Tayton-Martin: I think it is really the overwhelming interest that we are seeing in our immuno-oncology capabilities and the breadth of those, as Birgitte explained very eloquently, that there is just We have a lot more validation, and we have a lot of opportunity. It is not that we do not believe in the infectious disease assets and capabilities. It is just really where the momentum and the most significant value for what Evaxion has created and can do. I think it is very clear to us, very clear from the dialogue we have going on externally.

If we did not believe in the infectious disease assets we already have, we would not be still continuing to talk about them with partners. We believe there is value there. This is really about maximizing our own current resources around where we can see a lot of engagement and opportunity. I hope that answers the question.

Thomas Flaten: Yeah, that's great. Speaking of partnerships, any news we can anticipate from the ongoing collaboration with Merck on the infectious disease side?

Helen Tayton-Martin: Not that I can share today.

Thomas Flaten: Okay. Just one for Birgitte. Have you guys looked at, and you may have presented this in the past, and I apologize if you have, the correlation between CD8+ response and clinical response? Given that you had broad-based CD4+, we can kind of write that off as a universal response, but what about the CD8+ correlating to clinical response?

Helen Tayton-Martin: I'll let Birgitte take that one.

Birgitte Rønø: Yeah. No, it is a really good question. For the few patients that are not responding to study therapy, we actually do not have a strong immune dataset because they are early progressors. I would say the dataset we have available currently cannot fully answer that question.

Thomas Flaten: Got it. Appreciate it. No worries. Thanks for taking the questions.

Birgitte Rønø: Thank you.

Operator: Thank you. We are now going to take the next question. This one comes from Jason McCarthy from Maxim Group. Please go ahead.

Michael Okunewitch: Hey, guys. Good morning. This is Michael Okunewitch. I wanted to see if you could talk just a little bit about the expansion strategy for EVX-01, and is this something where you would need to do some smaller proof of concept or preclinical work and then seek partners, or is the melanoma validation itself sufficient to support expansion in those partner discussions?

Helen Tayton-Martin: Great question. We believe, and certainly the engagement that we have is very much around the validation we've already seen in advanced melanoma, which I think is a distinction for the Evaxion platform and clinical data. I think what we've been able to highlight is where, as Birgitte showed on the slides, that we have already done quite a bit of work to look at other indications that are potentially possible with the EVX-01 approach alone. I think what's also interesting to us and to partners is we can go beyond neoantigens in a personalized setting.

So, there could be the indications where a combination of personalized and ERVs is feasible, and that doesn't really change the process of making and delivering the vaccine. So, it opens up opportunity for where we currently are. We can take the current clinical package, we can take the ability of AI-Immunology to derive neoantigens and other antigens, and potentially move forward quickly into other initial, potentially phase II settings in other indications. I think that's a real advantage from where we are right now. Those are the sort of issues and questions that we're looking at in terms of where's the best opportunity and how to broaden out scope. It's again, lots of opportunity.

It's working through best fit, best setting, best antigens.

Michael Okunewitch: Thank you. Then, just with the strategic refocusing, how does that impact your plans for the autoimmune platform? Are you still planning to build this out, given that it is earlier along in that value creation pipeline and likely requires less resources versus clinical stage assets?

Helen Tayton-Martin: Yeah. No, great question. We are planning to complete. We have set out to identify the right targets for concept testing in autoimmune disease. Obviously, we're looking at ways of reducing immune inflammation in different settings, and that concept testing has progressed. We anticipate completing the validation of that, the work in the lab to do some testing around those concepts. I think we plan to at least complete that work to see whether we can show a compelling case for how we would take those programs forward, again, potentially with partnerships.

It's not requiring additional resource at the moment, and we plan to complete that work so that we can actually talk more about the scope for AI-Immunology to deliver in the autoimmune space. That's ongoing. That won't stop right now.

Michael Okunewitch: Thank you. Just one follow-up on that one, and I'll hop back into the queue. Just when thinking about that validation work that you need to get a partnerable package, what does that actually entail? Would this be producing an IND-ready product candidate for a specific disease, more along the lines of target discovery? I'm trying to understand what level of validation you need before you can bring it to partners.

Helen Tayton-Martin: I think that depends. I'll ask Birgitte to just comment on thoughts about where we are and the value of what we think we can generate, but I think we'll be early, basically.

Birgitte Rønø: Yeah. We have so far developed two therapeutic concepts. One is a tolerogenic vaccine that aims at re-educating the immune system towards self-tolerance. The AI-Immunology team and the bioinformaticians have worked on this concept. We are slowly getting ready in the lab to test some of these concepts. Then we have the other therapeutic approach, which is based on an autoantibody binders, and that is with the aim of reducing levels of pathogenic autoantibodies. We have started talking about these concepts and presenting at different conferences, so we hope that we'll be able to at least get some interest from potential partners early on, so before even having a defined product candidate.

Helen Tayton-Martin: So, it's really early proof of concept.

Birgitte Rønø: Yeah.

Michael Okunewitch: All right. Thank you very much. I appreciate the additional clarity.

Birgitte Rønø: Thank you.

Operator: Thank you. We're now going to take the next question. This one comes from Charles Wallace from H.C. Wainwright. Please go ahead.

Charles Wallace: Hi. Thanks for taking my question. Maybe the first from me. Now with the two positive phase III cancer vaccine readouts in the field, INTerpath-001 in adjuvant melanoma, and then just two days ago, the REGAL study at transplant-ineligible AML. I am just curious, regarding your pipeline, where is the interest specifically? Is it more in the personalized vaccine approach or in the off-the-shelf vaccine approach? That is my first question. Thank you.

Helen Tayton-Martin: Okay. I would definitely say it is in both, to the extent that we can share anything at all at this stage. I think that the broader potential across indications is definitely of interest, but clearly there are advantages in an off-the-shelf vaccine in terms of simpler supply chain, simpler delivery, simpler ability to deliver a product, and that is obviously of significant interest. However, at this point, that is not clinically validated. There is a belief in the personalized vaccine approach that can deliver clinically. We have shown that, others have shown that. And off-the-shelf is very much of interest, and it is really about moving along to clinical validation.

So, I would say there is equal interest in both areas at the moment.

Charles Wallace: Okay. That is helpful. And then I guess, on the infectious disease programs, the out-license program, EVX-B3, and then also the co-development program of EVX-B2. Can we assume that nothing is really changed in these two programs? Yeah, that is my next question. Thank you.

Helen Tayton-Martin: B3 is obviously out-licensed in a collaboration with MSD and is moving forward. The further updates from that will really come as a result of the MSD activities. And the B2 program is in collaboration with Afrigen and our RNA platform, and again, things have continued there. There will be data packages for B2, as with B1 and B4, as well as B1, as I mentioned in my comments, that are available for that we have continued to build on during the course of this year and are available, will be available in those partnering conversations.

So, from a partner perspective, B3 is moving along with MSD, and in the fullness of time, we will be able to talk more about that, but that is really driven off the next stages with them. And so things have not moved significantly from our perspective at this point until we hit the next point with that one.

Charles Wallace: Great. Thanks for taking my questions.

Helen Tayton-Martin: Okay, great.

Operator: Thank you. We are now going to take the next question. This one is from Danya Ben-Hail from JonesTrading. Please go ahead.

Danya Ben-Hail: Hi. Thank you for taking our questions. To follow up on the previous ones, can you share if there are any questions, diligence that potential partners have around EVX-01?

Helen Tayton-Martin: Not really, but I can talk to the fact that they ask all the questions, many questions that would be asked in this setting too, is really understanding turnaround time, the depth of the immune responses that we see, the correlations there, the quality of the antigens and the scoring that we generate. Really looking very closely, given that the whole world, the whole landscape around cancer vaccines has now shifted gears, it is really important to understand key scientific differentiators and also platform delivery opportunities where maybe there is scope to reduce the timeframe, they look at the modality of delivery, et cetera.

So all the sorts of things that come with drilling into how a product platform like this works. Then thinking about that more broadly in terms of different indication contexts, which is very much what we are doing too.

Danya Ben-Hail: Mm-hmm. Thank you. For the manufacturing, are you working on speeding up the vein-to-vein from the seven weeks you mentioned?

Helen Tayton-Martin: We know that it can be done. Birgitte, do you want to comment on the things that we are aware of?

Birgitte Rønø: Yes. The way that we have set up the supply chain is in a decentralized manner, meaning that we have been working with multiple different CDMOs. There is definitely an opportunity to get all of these many activities under one roof to reduce the manufacturing time. There has also been global shipping, going from the clinical site to the sequencing facility and for the drug product to be shipped back to the clinical site. This adds up in those overall timelines. There will be multiple ways that the turnaround time could be significantly reduced.

Danya Ben-Hail: Great. Thank you for that. Last question about EVX-04. When should we get more details on the clinical trial design?

Birgitte Rønø: We will be, as Helen Tayton-Martin mentioned, presenting target validation data at ASH in December. We are also running fast towards clinical trial application later this year. At that time point, we will most likely be able to share more details around patient population and trial design.

Danya Ben-Hail: Perfect. Thank you very much.

Helen Tayton-Martin: Thank you.

Operator: Thank you. As a reminder, to ask a question, you will need to press star, one, and one on your telephone. That is star, one, and one to ask a question. There seems to be no further questions for today. I will now hand the call back to Helen Tayton-Martin for closing remarks.

Helen Tayton-Martin: Thank you. Thank you very much for listening to our strategy and business update for Q3 today. We are very excited about the path forward for Evaxion, and thanks for the questions. Thank you.

Operator: Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.